STONEGATE SYSTEMSThis week half the industry decided research compounds are basically legal now, a federal judge handed a research-labeled seller 21 months, and neither of those sentences contradicts the other. Here is what actually happened, and what to do about it on your store.
The vote everyone is misreading
On July 23-24, the FDA's Pharmacy Compounding Advisory Committee met to consider whether seven research compounds should be added to the Section 503A bulk substances list - the list of what compounding pharmacies may use to fill patient-specific prescriptions. The committee recommended six of the seven. It did so against the FDA's own scientific reviewers, whose briefing documents recommended against all seven for lack of safety and efficacy data. One compound was voted down on the same grounds.
Within hours the takes were everywhere: the wall is coming down, the compounds are going mainstream, research stores are about to be legitimized. If you sell to researchers for a living, none of that is your news. Three reasons.
- An advisory recommendation is not approval. The committee advises. The FDA is not obligated to follow it, and even if it accepts every recommendation, nothing changes until a formal notice-and-comment rulemaking finishes. That is a process measured in months to years, not news cycles.
- It is the wrong lane. A 503A listing would let licensed pharmacies compound these substances for individual prescriptions. It says nothing about retail research-use sale. Your store's legal posture on July 25 is identical to its posture on July 22.
- The staff position is the part underwriters will remember. The agency's own reviewers put in writing that none of the seven met the criteria. If anything, the paper trail against casual human-use framing got longer this week, not shorter.
And while the committee was voting, the other half of the enforcement picture showed up on schedule. On July 23 the U.S. Attorney for the Western District of Michigan announced a 21-month federal prison sentence for a 35-year-old Michigan man who helped import unapproved, misbranded drugs - research compounds included - from China and sell them online. Both sites involved carried research-only labels. Prosecutors said the operators knew customers were using the products personally, and the label did not survive contact with the rest of the evidence.
That is the pattern we have been tracking all year: the warning-letter era is winding down and the enforcement mix is shifting toward import seizures and criminal outcomes. Letters still come, but the March 31 batch of seven letters already read less like warnings and more like documentation. A sentencing on the same day as the advisory vote is the whole 2026 enforcement story in one news cycle: the compounding lane may slowly open for pharmacies, while the consequences for a research store that reads like a pharmacy keep getting heavier.
The vote changed what pharmacies might one day compound. It changed nothing about what your store can say.
The regulator that answers in 48 hours
The FDA takes months to act. A processor's underwriting desk takes days, and it reads your site the same way. Across the processor and underwriting guides published for this category, the most consistently documented reason applications decline is site language - not credit history, not volume, not the products themselves.
Three things underwriters actually pull up before they approve a research-supply merchant:
- Claim language, anywhere on the domain. Not just product pages - blog posts, FAQs, category descriptions, image alt text. One benefit sentence anywhere reclassifies the file from "research supplier" to "unlicensed pharmacy," and the review stops there.
- Policy pages that exist and agree with card-network rules. Visible refund, shipping, and terms pages, consistent with what checkout promises. One 2026 underwriting guide attributes nearly a third of initial-screen declines to missing or unclear refund policies alone. It is the cheapest fix on this list and the most commonly skipped.
- Whether the totality matches the disclaimer. Accurate product descriptions, no human-use accessories in the cart, no wellness-clinic positioning. Underwriters decline stores that read like weight-loss brands wearing a research label, because their risk desk knows exactly what happens to those merchants six months in.
Notice that this is the same read the FDA runs, on a faster clock. A store built to survive processor underwriting review is the same store that does not match the language quoted in warning letters. You are not maintaining two compliance postures. You are maintaining one, and two different reviewers keep grading it. The full breakdown of the underwriting exam is in our merchant account guide.
Teardown pattern of the week: the FAQ and the linked community
Each issue we pull one recurring pattern from the published FDA letters - not to name anyone the agency has not already named, but because the same mistakes repeat across sites that believed they were careful. This week: the two places scrubbed stores still leak.
The FAQ page. Operators sanitize product pages and then answer "what is this compound studied for" in the FAQ, in plain efficacy language. The published letters quote exactly this kind of page. The agency's intended-use analysis reads the whole site as one document, so a benefit claim in an FAQ sits legally adjacent to the disclaimer it contradicts - and in the letters, the two get quoted side by side. Your FAQ is product copy. It gets held to product-copy standards.
The linked community. Discord invites, forum embeds, reposted customer content. Analyses of the 2024-2026 letters make the mechanism clear: content a store links to, republishes, or amplifies gets attributed to the store, and hosted customer reviews describing personal use were cited in the March letters as the company's own marketing. If your footer links a channel where members swap use reports, that conversation is part of your site's totality. You do not get credit for not having written it.
Neither pattern is exotic. Both appear on sites whose product pages would pass a spot check, which is the point: the letters are built from the pages nobody was watching. The full letter tracker maps every published letter to the element that triggered it.
Do this on your store this week
- Read your FAQ as an underwriter. Every answer that describes what a compound does in a person gets rewritten to describe the product spec, or deleted.
- Click every outbound link on your site. If the destination hosts human-use discussion you would not print on a product page, unlink it. Same for embedded reviews - off, or moderated hard.
- Open your refund, shipping, and terms pages on a phone. If any is missing, buried, or contradicts checkout, fix it before you next talk to a processor. It is the single most documented preventable decline.
That's issue one. I read the letters, the dockets, and the processor bulletins every week because I build and maintain these stores for a living - the brief is the part of that reading you can act on. No consumer content, no hype, no compound worship. If something moves midweek that can't wait, subscribers hear about it first.
- Zane, Stonegate Systems
The RUO Operator is general information for store operators, compiled from public records and published FDA correspondence. Findings discussed here are patterns matching language quoted in published FDA warning letters. It is not legal advice, and Stonegate Systems is not a law firm.